Drug Trial Radar · NCT06825494
Clinical Studies for the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
194
Planned (sponsor's estimate)
Start
Apr 8, 2025
Primary completion
Mar 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
LM-108 injection+Penpulimab+ Oxaliplatin+CapecitabineDrug
LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.
Tislelizumab+Oxaliplatin+CapecitabineDrug
Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1). Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.
LM-108 injection 10mg/kg +penpulimabDrug
LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.
LM-108 injection 600mg + penpulimabDrug
LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.
enpulimab+ Oxaliplatin+CapecitabineDrug
Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLT) eventsTime frame: From first dose to 21days after first dose
- Progression-free survival (PFS)Time frame: The estimated time from randomization to patient disease progression was 10 months
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Not yet recruiting
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China · Not yet recruiting
Peking University Shenzhen Hospita
Shenzhen, Guangdong, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
Tangshan People's Hospital
Tangshan, Hebei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Nanyang Second General Hospital
Nanyang, Henan, China · Not yet recruiting
Ping mei shen ma Medical Group General Hospital
Pingdingshan, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
The second xiangya hospital of central south university
Changsha, Hunan, China · Not yet recruiting
Inner Mongolia Hospital of Peking University Cancer Hospita
Hohhot, Inner Mongolia, China · Not yet recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
NanJing Drum Tower Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
XuZhou Central Hospital
Xuzhou, Jiangsu, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
The First Hospital Of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, China · Not yet recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
First Hospital of Shangxi Medical University
Taiyuan, Shangxi, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospita
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.